EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS
EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT AND PREVENTION OF TUBERCULOSIS
复制标题
DOI：
10.1093/clind/15.supplement_1.s282
复制
发表时间：
1992-11-01
影响因子：
11.8
通讯作者：
OBRIEN, R
中科院分区：
文献类型：
--
作者：
HOPEWELL, P;CYNAMON, M;OBRIEN, R
本指南涉及对治疗和预防（二级预防）结核分枝杆菌感染的新型抗细菌药物的评价。患者可根据临床和/或微生物学标准入组临床试验。治疗方案可能包括药物组合；建议进行随机、主动对照、比较临床试验。如果在随访期间可以获得适当的样本进行培养，而不会使患者面临不必要的风险，那么微生物结果的评估是至关重要的。预防可能需要一种药物，并且首选类似的研究设计。
This guideline addresses the evaluation of new antimycobacterial drugs in the treatment and prevention (secondary prophylaxis) of infection by M. tuberculosis. Patients may be enrolled in clinical trials on the basis of clinical and/or microbiological criteria. A therapeutic regimen will likely include a combination of drugs; a randomized, active-control, comparative clinical trial is recommended. If appropriate samples can be obtained for culture during follow-up without placing the patient at unwarranted risk, the assessment of microbiological outcome is paramount. Prophylaxis will probably require a single drug, and a similar study design is preferred.